Key terms
About EYPT
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EYPT news
Apr 12
2:15pm ET
Strong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapies
Apr 03
6:46am ET
EyePoint should be bought on recent weakness, says Mizuho
Apr 02
7:03am ET
EyePoint expands scientific advisory board with three appointments
Mar 18
7:01am ET
EyePoint reports inducement grants under Nasdaq listing rule
Mar 11
12:50am ET
Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
Mar 09
1:01am ET
Bad News for Eyepoint Pharma Stock: This New Risk Has Been Added
Mar 08
10:45am ET
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Clinical Trials and Market Expansion Potential
Mar 07
8:51pm ET
Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)
Mar 07
12:45pm ET
EyePoint Pharmaceuticals’ EYP-1901 Shows Promising Potential in Wet AMD Treatment: A Strong Buy Recommendation
Mar 07
7:05am ET
EyePoint expects cash to fund operations through Phase 3 trial data in 2026
Mar 07
7:03am ET
EyePoint reports Q4 EPS (33c), consensus (49c)
Mar 07
12:06am ET
EyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy Rating
Mar 05
7:23am ET
EyePoint share weakness a buying opportunity, says Cantor Fitzgerald
Mar 04
7:45pm ET
Buy Rating Affirmed for EyePoint Pharmaceuticals Amid Strategic Leadership Changes and Promising Pipeline Outlook
Mar 04
7:10am ET
EyePoint appoints Ribeiro as Chief Medical Officer
Feb 16
8:30am ET
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and EyePoint Pharmaceuticals (EYPT)
Feb 16
7:06am ET
EyePoint reports inducement grants under Nasdaq listing rule
Feb 15
6:46am ET
EyePoint price target raised to $39 from $30 at Mizuho
Feb 07
10:55am ET
EYP-1901 Shows Promising Results in Phase 2 Study: A Strong Buy for EyePoint Pharmaceuticals
Feb 07
10:50am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)
Feb 07
10:40am ET
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Humana (HUM)
Feb 05
6:15am ET
EyePoint Pharmaceuticals Earns Buy Rating Following Promising EYP-1901 Clinical Trial Results
Feb 04
7:35am ET
EyePoint announced results from new subgroup analyses from Phase 2 DAVIO 2 trial
Jan 31
8:45am ET
Largest borrow rate increases among liquid names
Jan 22
9:59am ET
AMD downgraded, American Airlines upgraded: Wall Street’s top analyst calls
Jan 22
5:25am ET
EyePoint initiated with an Overweight at JPMorgan
Jan 16
6:10pm ET
EyePoint director sells $37.2M in common stock
No recent news articles are available for EYPT
No recent press releases are available for EYPT
EYPT Financials
Key terms
Ad Feedback
EYPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EYPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
